Recombinant Vesicular Stomatitis Virus Tumor Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current oncolytic virus therapies lack specificity for tumor cells and broad spectrum efficacy across multiple tumor types, limiting their therapeutic effectiveness and safety.
Innovation Solution
Development of a recombinant vesicular stomatitis virus expressing specific G proteins, such as those with GenBank indices X03633.1 and DQ408670.1, which enhance binding force to tumor cells through specific receptors, allowing for targeted infection and killing of various tumor cells while minimizing impact on normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional oncolytic viruses are used, then virus replication in cancer cells is achieved, but tumor cell specificity and broad spectrum efficacy are insufficient
Solution Approach 1:
The patent applies local quality by engineering the virus envelope glycoprotein to specifically recognize and bind to particular tumor cell surface receptors. The modified glycoprotein confers localized targeting capability to the virus, enabling it to distinguish tumor cells from normal cells through receptor-specific binding, thereby achieving high tumor cell specificity while maintaining broad spectrum efficacy across multiple tumor types that express the target receptor.
2Force
If virus genome is modified to target specific receptors, then binding force to tumor cells is enhanced, but virus replication capability may be affected
Solution Approach 1:
The patent extracts and modifies only the envelope glycoprotein gene from the viral genome while leaving the rest of the viral replication machinery intact. This targeted modification approach allows enhancement of binding force to tumor cells through glycoprotein engineering without disrupting the virus's intrinsic replication capability, as the core replication genes remain unchanged and functional.
3Productivity
If oncolytic virus therapy is applied, then tumor killing efficiency is achieved, but side effects on normal tissues occur
Solution Approach 1:
The patent uses tumor-specific surface receptors as intermediaries to mediate virus-tumor cell interaction. The modified viral glycoprotein binds specifically to these receptor intermediaries on tumor cell surfaces, directing the virus to tumor cells while preventing binding to normal cells that lack or have low levels of the target receptor. This intermediary mechanism enables high tumor killing efficiency with minimal side effects on normal tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant virus demonstrates strong specificity and broad spectrum killing efficacy against multiple tumor types with reduced side effects on normal tissues, achieving high targeting ability and significant tumor killing effects.
Implementation Method 1
The G protein of some vesicular stomatitis viruses can achieve a high binding force of the vesicular stomatitis viruses to some tumor cells through specific receptors on the surfaces of the tumor cells
Data Source
AI summary
Provided is a recombinant vesicular stomatitis oncolytic virus. The recombinant vesicular stomatitis oncolytic virus expresses a G protein, and the G protein has the following amino acid sequence: (a) SEQ ID NO: 1; (b) SEQ ID NO: 2; or (c) an amino acid sequence having at least 80% homology to (a) or (b).